JP2023503857A5 - - Google Patents
Info
- Publication number
- JP2023503857A5 JP2023503857A5 JP2022528248A JP2022528248A JP2023503857A5 JP 2023503857 A5 JP2023503857 A5 JP 2023503857A5 JP 2022528248 A JP2022528248 A JP 2022528248A JP 2022528248 A JP2022528248 A JP 2022528248A JP 2023503857 A5 JP2023503857 A5 JP 2023503857A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- herv
- acid encoding
- recombinant mva
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19210369.5 | 2019-11-20 | ||
| EP19210369 | 2019-11-20 | ||
| EP20193706.7 | 2020-08-31 | ||
| EP20193706 | 2020-08-31 | ||
| PCT/EP2020/082926 WO2021099586A1 (en) | 2019-11-20 | 2020-11-20 | Recombinant mva viruses for intratumoral and/or intravenous administration for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023503857A JP2023503857A (ja) | 2023-02-01 |
| JP2023503857A5 true JP2023503857A5 (cg-RX-API-DMAC7.html) | 2023-11-06 |
| JP7644111B2 JP7644111B2 (ja) | 2025-03-11 |
Family
ID=73740362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022528248A Active JP7644111B2 (ja) | 2019-11-20 | 2020-11-20 | がんを治療するための腫瘍内及び／または静脈内投与用組み換えｍｖａウイルス |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230190922A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4061406A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7644111B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220106775A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114867491B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020387646A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022009798A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3159588A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL293009B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022005664A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021099586A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12194157B2 (en) | 2020-04-09 | 2025-01-14 | Finncure Oy | Carrier for targeted delivery to a host |
| FI20215508A1 (en) | 2020-04-09 | 2021-10-10 | Niemelae Erik Johan | Mimetic nanoparticles to prevent the spread of new coronaviruses and reduce the rate of infection |
| WO2023118508A1 (en) * | 2021-12-23 | 2023-06-29 | Bavarian Nordic A/S | Recombinant mva viruses for intraperitoneal administration for treating cancer |
| EP4452306A1 (en) * | 2021-12-23 | 2024-10-30 | Bavarian Nordic A/S | Therapy for modulating immune response with recombinant mva encoding il-12 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4486530A (en) | 1980-08-04 | 1984-12-04 | Hybritech Incorporated | Immunometric assays using monoclonal antibodies |
| US4411993A (en) | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
| USRE32011E (en) | 1981-12-14 | 1985-10-22 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
| US4543439A (en) | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4902614A (en) | 1984-12-03 | 1990-02-20 | Teijin Limited | Monoclonal antibody to human protein C |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| DE3689123T2 (de) | 1985-11-01 | 1994-03-03 | Xoma Corp | Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung. |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| EP0436597B1 (en) | 1988-09-02 | 1997-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| EP1820858B1 (en) | 1991-03-01 | 2009-08-12 | Dyax Corporation | Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof |
| ATE414768T1 (de) | 1991-04-10 | 2008-12-15 | Scripps Research Inst | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| DE69435171D1 (de) | 1993-09-14 | 2009-01-08 | Pharmexa Inc | Pan dr-bindeproteinen zur erhöhung der immunantwort |
| AUPO390396A0 (en) | 1996-11-29 | 1996-12-19 | Csl Limited | Novel promiscuous T helper cell epitopes |
| SK4272001A3 (en) | 1998-10-05 | 2003-02-04 | Pharmexa As | Methods for therapeutic vaccination |
| UA76731C2 (uk) | 2000-11-23 | 2006-09-15 | Баваріан Нордік А/С | Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації |
| DE60235041D1 (de) | 2001-11-30 | 2010-02-25 | Us Gov Health & Human Serv | Und ihre verwendung |
| EP2345665A3 (en) | 2001-12-04 | 2012-02-15 | Bavarian Nordic A/S | Flavivirus NS1 subunit vaccine |
| NZ592082A (en) | 2008-11-27 | 2013-03-28 | Bavarian Nordic As | Promoters for recombinant viral expression |
| US8394385B2 (en) | 2009-03-13 | 2013-03-12 | Bavarian Nordic A/S | Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines |
| EP2800762B1 (en) | 2012-01-03 | 2018-01-03 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Native and agonist ctl epitopes of the muc1 tumor antigen |
| WO2013189611A1 (en) | 2012-06-22 | 2013-12-27 | Bavarian Nordic A/S | Poxviral vectors for low antibody response after a first priming immunization |
| WO2014037124A1 (en) * | 2012-09-04 | 2014-03-13 | Bavarian Nordic A/S | Methods and compositions for enhancing vaccine immune responses |
| EP2908851A1 (en) | 2012-10-19 | 2015-08-26 | Bavarian Nordic Inc. | Methods and compositions for the treatment of cancer |
| EP2912183B1 (en) | 2012-10-28 | 2020-05-06 | Bavarian Nordic A/S | Pr13.5 promoter for robust t-cell and antibody responses |
| KR102499737B1 (ko) * | 2014-05-13 | 2023-02-13 | 버베리안 노딕 에이/에스 | 종양 항원을 발현하는 재조합 폭스바이러스 및 면역 체크포인트 분자 길항제 또는 효현제로 암을 치료하기 위한 복합 요법 |
| KR20150135148A (ko) | 2014-05-23 | 2015-12-02 | 주식회사 제넥신 | Pd-l1 융합 단백질 및 이의 용도 |
| ES2901468T3 (es) | 2015-07-31 | 2022-03-22 | Bavarian Nordic As | Promotores para mejorar la expresión en poxvirus |
| CN111050790B (zh) | 2017-08-24 | 2024-07-12 | 巴法里安诺迪克有限公司 | 通过静脉内施用重组mva和抗体治疗癌症的组合疗法 |
| DK3676285T3 (da) * | 2017-09-01 | 2026-01-19 | Inprother Aps | Vaccine til anvendelse i profylakse og/eller behandling af en sygdom |
| CA3119503A1 (en) * | 2018-11-20 | 2020-05-28 | Bavarian Nordic A/S | Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l |
-
2020
- 2020-11-20 US US17/778,374 patent/US20230190922A1/en active Pending
- 2020-11-20 EP EP20820341.4A patent/EP4061406A1/en active Pending
- 2020-11-20 CA CA3159588A patent/CA3159588A1/en active Pending
- 2020-11-20 MX MX2022005664A patent/MX2022005664A/es unknown
- 2020-11-20 BR BR112022009798A patent/BR112022009798A2/pt unknown
- 2020-11-20 KR KR1020227020160A patent/KR20220106775A/ko active Pending
- 2020-11-20 AU AU2020387646A patent/AU2020387646A1/en active Pending
- 2020-11-20 CN CN202080086850.1A patent/CN114867491B/zh active Active
- 2020-11-20 WO PCT/EP2020/082926 patent/WO2021099586A1/en not_active Ceased
- 2020-11-20 IL IL293009A patent/IL293009B2/en unknown
- 2020-11-20 JP JP2022528248A patent/JP7644111B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023503857A5 (cg-RX-API-DMAC7.html) | ||
| JP2022507744A5 (cg-RX-API-DMAC7.html) | ||
| Schlom | Therapeutic cancer vaccines: current status and moving forward | |
| JP2017515841A5 (cg-RX-API-DMAC7.html) | ||
| JP2018139586A5 (cg-RX-API-DMAC7.html) | ||
| Wiedermann et al. | Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines | |
| CA2293692A1 (en) | Methods and reagents for vaccination which generate a cd8 t cell immune response | |
| RU2016148311A (ru) | Комбинированная терапия для лечения рака с помощью рекомбинантного поксвируса, экспрессирующего опухолевый антиген, и антагониста или агониста молекулы иммунной контрольной точки | |
| WO2004016643A3 (en) | Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines | |
| Lubaroff | Prostate cancer vaccines in clinical trials | |
| JP2023503858A5 (cg-RX-API-DMAC7.html) | ||
| Chang et al. | Vaccinating against cancer: getting to prime time | |
| US12246038B2 (en) | Compositions for inducing an immune response | |
| JP2022512595A5 (cg-RX-API-DMAC7.html) | ||
| Wang et al. | Current status and progress of the development of prostate cancer vaccines | |
| Shu et al. | Virus-like particles presenting the FGF-2 protein or identified antigenic peptides promoted antitumor immune responses in mice | |
| Evans et al. | Vaccine therapy for cancer—fact or fiction? | |
| Ruan et al. | Enhanced synergistic anti‐Lewis lung carcinoma effect of a DNA vaccine harboring a MUC 1‐VEGFR 2 fusion gene used with GM‐CSF as an adjuvant | |
| Lin et al. | Enhanced immunogenicity and antitumour effects with heterologous prime-boost regime using vaccines based on MG7-Ag mimotope of gastric cancer | |
| Kudo-Saito et al. | Intratumoral delivery of vector mediated IL-2 in combination with vaccine results in enhanced T cell avidity and anti-tumor activity | |
| RU2015116904A (ru) | Иммунизация вектором на основе вируса бешенства, экспрессирующим чужеродный белковый антиген | |
| RU2021117499A (ru) | Терапия для лечения рака с помощью внутриопухолевого и/или внутривенного введения рекомбинантного mva, кодирующего 4-1bbl (cd137l) и/или cd40l | |
| Azimifar et al. | Interleukin gene delivery for cancer gene therapy: In vitro and in vivo studies | |
| WO2007058235A1 (ja) | 融合蛋白質およびその薬学的用途 | |
| Shahreza et al. | GRP-based vaccines as a novel approach in cancer immunotherapy: mechanisms, challenges, and prospects |